Comparison of post-marketing surveillance approaches regarding infections related to tumor necrosis factor inhibitors (TNFi's) used in treatment of autoimmune diseases. [electronic resource]
Producer: 20190801Description: 733-744 p. digitalISSN:- 1744-764X
- Adalimumab -- administration & dosage
- Adverse Drug Reaction Reporting Systems -- statistics & numerical data
- Autoimmune Diseases -- drug therapy
- Etanercept -- administration & dosage
- Humans
- Immunologic Factors -- administration & dosage
- Infections -- chemically induced
- Pharmacovigilance
- Product Surveillance, Postmarketing -- methods
- Tumor Necrosis Factor-alpha -- antagonists & inhibitors
- United States
- United States Food and Drug Administration
No physical items for this record
Publication Type: Comparative Study; Journal Article
There are no comments on this title.
Log in to your account to post a comment.